Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IACH MATH 2020 | CAR T-cell therapy for AML

Arnon Nagler • 7 Jun 2020
IACH MATH 2020
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia Axicabtagene ciloleucel CAR-T Tisagenlecleucel

Arnon Nagler, MD, Sheba Medical Center, Tel-Aviv, Israel, discusses the exciting field of CAR T-cell therapy in acute myeloid leukemia (AML). Although the success of CAR T-cell therapy in other fields has not been translated into treatment for AML, Prof. Nagler reveals that research is progressing and in the future CAR T-cells for AML might be a possible treatment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Arnon Nagler

Molecular profiling and MRD are reshaping transplant decision-making in AML
3:19
Molecular profiling and MRD are reshaping transplant decision-making in AML
Arnon Nagler • 15 Jun 2026
EBMT analysis: alloSCT may overcome FLT3-ITD risk in CBFB::MYH11-positive AML
3:26
EBMT analysis: alloSCT may overcome FLT3-ITD risk in CBFB::MYH11-positive AML
Arnon Nagler • 15 Jun 2026
Targeted therapies and immunotherapy are redefining transplantation in AML
3:18
Targeted therapies and immunotherapy are redefining transplantation in AML
Arnon Nagler • 15 Jun 2026
Umbilical cord blood transplantation in adults: revisiting its role in modern practice
2:40
Umbilical cord blood transplantation in adults: revisiting its role in modern practice
Arnon Nagler • 15 Jun 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals